Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Academic Article
Publication Date:
2022
Short description:
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials / Danese, S., Vermeire, S., Zhou, W., Pangan, A.L., Siffledeen, J., Greenbloom, S., Hebuterne, X., D'Haens, G., Nakase, H., Panes, J., Higgins, P.D.R., Juillerat, P., Lindsay, J.O., Loftus, E.V., Sandborn, W.J., Reinisch, W., Chen, M.-H., Sanchez Gonzalez, Y., Huang, B., Xie, W., et al.. - In: THE LANCET. - ISSN 1474-547X. - 399:10341(2022), pp. 2113-2128. [10.1016/S0140-6736(22)00581-5]
Iris type:
1.1 Articolo in rivista
List of contributors:
Danese, S.; Vermeire, S.; Zhou, W.; Pangan, A. L.; Siffledeen, J.; Greenbloom, S.; Hebuterne, X.; D'Haens, G.; Nakase, H.; Panes, J.; Higgins, P. D. R.; Juillerat, P.; Lindsay, J. O.; Loftus, E. V.; Sandborn, W. J.; Reinisch, W.; Chen, M. -H.; Sanchez Gonzalez, Y.; Huang, B.; Xie, W.; Liu, J.; Weinreich, M. A.; Panaccione, R.
Published in: